ess Is More: Optimized pharmacotherapy with improved coNtinuity of CarE in hospitaLized oLder peOple

Recruiting

Conditions: aandoening overstijgend, polyfarmacie
Polypharmacy
Usage of multiple medicines

Registration Number: NL-OMON53950

Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 2576

Inclusion Criteria

• 70 years or older
• Polypharmacy, the use of 5 or more regular medications, defined as authorised
medications with registration numbers, used for more than 30 days. Topical
preparations are excluded from this definition.
• Admitted to hospital through the ED (which comprises both the general
emergency department and the cardiac emergency department)
• Length of hospitalisation more than 24 hours
• Completed medication verification
• DRA prediction percentage of 23.0% or higher (see research protocol chapter
4.2.1. for more extensive information)

Exclusion Criteria

• No informed consent by patient or a legal representative
• Participation in an interfering clinical trial
• Elective hospital admission
• Direct admission to the ICU (when medication verification as usual can*t be
executed, and therefore inclusion of patients as described in 10.2 is not
possible)
• A life expectancy of less than 3 months, which includes patients with
palliative treatment at home, direct admission to palliative care or palliative
care planned within 24 hours after index hospital admission.
• Patient or legal representative not able to speak Dutch.
• Follow-up of patient primarily by secondary caregivers. This refers to
situations where the secondary caregiver is in the lead of the medication list
of the patient instead of the GP or elderly care physician, for example in the
following patient groups:
o patients receiving intensive oncologic therapy
o patients in an organ- or stem cell transplantation procedure
o patients receiving intensive (chronic) psychiatric care, such as patients
admitted to a medical psychiatric unit
o patients on dialysis

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is the occurrence of DRreAs in the first 30 days after<br /><br>discharge. Drug relatedness of the admission will be determined using the<br /><br>AT-HARM10 tool, executed by trained pharmacy students. </p><br>

Secondary Outcome Measures